Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niels Pallisgaard

Showing results (11-20 of 68) with videos related to

Pageof 7
Sort By:
Cancer Genetics and Cytogenetics|February 24, 2006
Contribution of multiparameter genetic analysis to the detection of genetic alterations in hematologic neoplasia. An evaluation of combining G-band analysis, spectral karyotyping, and multiplex reverse-transcription polymerase chain reaction (multiplex RT-PCR)Birgitte S Preiss, Gitte B Kerndrup, Rikke K Pedersen, et al.
Plos One|April 16, 2015
Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancerKaren Lise Garm Spindler, Niels Pallisgaard, Rikke Fredslund Andersen, et al.
BMC Cancer|March 29, 2011
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancerKaren-Lise G Spindler, Niels Pallisgaard, Jan Lindebjerg, et al.
Blood|June 21, 2019
Prevalence and phenotypes of <i>JAK2</i> V617F and <i>calreticulin</i> mutations in a Danish general populationSabrina Cordua, Lasse Kjaer, Vibe Skov, et al.
Anticancer Research|February 11, 2014
Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research studyKaren-Lise G Spindler, Niels Pallisgaard, Rikke F Andersen, et al.
Acta Oncologica (Stockholm, Sweden)|August 14, 2020
Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancerAnders K Boysen, Niels Pallisgaard, Christina S A Andersen, et al.
Hematology (Amsterdam, Netherlands)|January 22, 2009
Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burdenThomas Stauffer Larsen, Niels Pallisgaard, Karin de Stricker, et al.
Lung Cancer (Amsterdam, Netherlands)|December 15, 2012
The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancerAnneli Dowler Nygaard, Karen-Lise Garm Spindler, Niels Pallisgaard, et al.
Oncology Reports|December 10, 2013
Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLCAnneli Dowler Nygaard, Karen-Lise Garm Spindler, Niels Pallisgaard, et al.
Journal of Circulating Biomarkers|September 23, 2017
Quantification of Cell-Free HER-2 DNA in Plasma from Breast Cancer Patients: Sensitivity for Detection of Metastatic Recurrence and Gene AmplificationPatricia Diana Sørensen, Rikke Fredslund Andersen, Niels Pallisgaard, et al.
Pageof 7

Showing results (11-20 of 68) with videos related to

Sort By:
Pageof 7
Cancer Genetics and Cytogenetics|February 24, 2006
Contribution of multiparameter genetic analysis to the detection of genetic alterations in hematologic neoplasia. An evaluation of combining G-band analysis, spectral karyotyping, and multiplex reverse-transcription polymerase chain reaction (multiplex RT-PCR)Birgitte S Preiss, Gitte B Kerndrup, Rikke K Pedersen, et al.
Plos One|April 16, 2015
Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancerKaren Lise Garm Spindler, Niels Pallisgaard, Rikke Fredslund Andersen, et al.
BMC Cancer|March 29, 2011
EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancerKaren-Lise G Spindler, Niels Pallisgaard, Jan Lindebjerg, et al.
Blood|June 21, 2019
Prevalence and phenotypes of <i>JAK2</i> V617F and <i>calreticulin</i> mutations in a Danish general populationSabrina Cordua, Lasse Kjaer, Vibe Skov, et al.
Anticancer Research|February 11, 2014
Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research studyKaren-Lise G Spindler, Niels Pallisgaard, Rikke F Andersen, et al.
Acta Oncologica (Stockholm, Sweden)|August 14, 2020
Circulating tumor DNA as a marker of minimal residual disease following local treatment of metastases from colorectal cancerAnders K Boysen, Niels Pallisgaard, Christina S A Andersen, et al.
Hematology (Amsterdam, Netherlands)|January 22, 2009
Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burdenThomas Stauffer Larsen, Niels Pallisgaard, Karin de Stricker, et al.
Lung Cancer (Amsterdam, Netherlands)|December 15, 2012
The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancerAnneli Dowler Nygaard, Karen-Lise Garm Spindler, Niels Pallisgaard, et al.
Oncology Reports|December 10, 2013
Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLCAnneli Dowler Nygaard, Karen-Lise Garm Spindler, Niels Pallisgaard, et al.
Journal of Circulating Biomarkers|September 23, 2017
Quantification of Cell-Free HER-2 DNA in Plasma from Breast Cancer Patients: Sensitivity for Detection of Metastatic Recurrence and Gene AmplificationPatricia Diana Sørensen, Rikke Fredslund Andersen, Niels Pallisgaard, et al.
Pageof 7